Abstract:Epidermolysis bullosa (EB) includes a group of rare skin diseases characterized by skin fragility with bullous formation in the skin, in response to minor mechanical injury, as well as varying degrees of involvement of the mucous membranes of the internal organs. EB is classified into simplex, junctional, dystrophic and mixed. The impact of the disease on patients is both physical and psychological, with the result that their quality of life is constantly affected. Unfortunately, there are still no approved treatments available to confront the disease, and treatment focuses on improving the symptoms with topical treatments to avoid complications and other infections. Stem cells are undifferentiated cells capable of producing, maintaining and replacing terminally differentiated cells and tissues. Stem cells can be isolated from embryonic or adult tissues, including skin, but are also produced by genetic reprogramming of differentiated cells. Preclinical and clinical research has recently greatly improved stem cell therapy, making it a promising treatment option for various diseases in which current medical treatments fail to cure, prevent progression, or alleviate symptoms. So far, stem cells from different sources, mainly hematopoietic and mesenchymal, autologous or heterologous have been used for the treatment of the most severe forms of the disease each one of them with some beneficial effects. However, the mechanisms through which stem cells exert their beneficial role are still unknown or incompletely understood and most importantly further research is required to evaluate the effectiveness and safety of these treatments. The transplantation of skin grafts to patients produced by gene-corrected autologous epidermal stem cells has been proved to be rather successful for the treatment of skin lesions in the long term in a limited number of patients. Nevertheless, these treatments do not address the internal epithelia-related complications manifested in patients with more severe forms.

Epidermolysis bullosa in oral health: clinical manifestations and salivary alterations

Oral Manifestations Of Epidermolysis Bullosa: Case Report.

Oral Manifestations And Challenges In Dental Management Of Epidermolysis Bullosa: Case Report

Hereditary epidermolysis bullosa: clinical-epidemiological profile of 278 patients at a tertiary hospital in São Paulo, Brazil

Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa

Epidermolysis Bullosa—A Kindler Syndrome Case Report and Short Literature Review

Pathological Mechanisms Involved in Epidermolysis Bullosa Simplex: Current Knowledge and Therapeutic Perspectives

A Catheter Securement Strategy for Patients with Epidermolysis Bullosa

[Clinical, histopathologic, immunofluorescent and ultrastructural estimation of 2 cases of epidermolysis bullosa acquisita]

The dental needs of children with Epidermolysis Bullosa and service delivery: a scoping review

Management of Skin Lesions in Patients with Epidermolysis Bullosa by Topical Treatment: Systematic Review and Meta-Analysis

Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives

Vesiculobullous Lesions of the Oral Cavity

Epidemiological Characteristics of Inherited Epidermolysis Bullosa in an Eastern European Population

Molecular pathology of the basement membrane zone in heritable blistering diseases:: The paradigm of epidermolysis bullosa

Autoimmunity and Cytokine Imbalance in Inherited Epidermolysis Bullosa

Stem Cell Therapies for Epidermolysis Bullosa Treatment

Epidermolysis Bullosa Acquisita-Current and Emerging Treatments

Investigational Treatments for Epidermolysis Bullosa

Epidemiology of epidermolysis bullosa in Chile

Economic burden and health-related quality of life in patients with epidermolysis bullosa in Spain